Skip to main content

Small biopharma company NanoViricides sees stock soar on coronavirus treatment claims

NanoViricides claims it's near clinical trials for a treatment, but a CNBC investigation found it has never tested a product in humans or made any revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.